Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...193194195196197198199200201202203...208209»
  • ||||||||||  ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
    Trial completion:  A Single Dose Study of SHR4640 in Healthy Male Volunteers (clinicaltrials.gov) -  Jul 3, 2018   
    P1,  N=40, Completed, 
    Phase classification: P2 --> P2a Recruiting --> Completed
  • ||||||||||  famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Trial termination:  A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer (clinicaltrials.gov) -  Apr 18, 2018   
    P2,  N=150, Terminated, 
    Recruiting --> Completed | Trial primary completion date: Sep 2018 --> Dec 2017 Active, not recruiting --> Terminated
  • ||||||||||  famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Trial completion:  A Study of Famitinib in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) -  Apr 18, 2018   
    P2b,  N=154, Completed, 
    Active, not recruiting --> Terminated Recruiting --> Completed
  • ||||||||||  famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Trial completion, Enrollment change:  A Phase I Study of Famitinib Malate in Patients With Solid Tumor (clinicaltrials.gov) -  Apr 18, 2018   
    P1,  N=55, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | N=29 --> 55
  • ||||||||||  famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) -  Apr 18, 2018   
    P1,  N=22, Active, not recruiting, 
    Recruiting --> Terminated; The applicant decided to close the study Recruiting --> Active, not recruiting | Trial completion date: Dec 2016 --> Jun 2019 | Trial primary completion date: Jun 2015 --> Dec 2018
  • ||||||||||  famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date:  Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma?FACT? (clinicaltrials.gov) -  Apr 17, 2018   
    P3,  N=543, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2016 --> Jun 2019 | Trial primary completion date: Jun 2015 --> Dec 2018 Trial completion date: Dec 2017 --> Jun 2019 | Trial primary completion date: Nov 2017 --> Nov 2018
  • ||||||||||  famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date:  A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor (clinicaltrials.gov) -  Apr 17, 2018   
    P2,  N=88, Active, not recruiting, 
    Trial completion date: Dec 2017 --> Jun 2019 | Trial primary completion date: Nov 2017 --> Nov 2018 Trial completion date: Jun 2016 --> Jun 2019 | Trial primary completion date: Jun 2016 --> Dec 2018
  • ||||||||||  famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Enrollment closed, Trial primary completion date:  A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) -  Apr 17, 2018   
    P2,  N=144, Active, not recruiting, 
    Trial completion date: Jun 2016 --> Jun 2019 | Trial primary completion date: Jun 2016 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Dec 2018
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301) (clinicaltrials.gov) -  Apr 17, 2018   
    P2,  N=80, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Dec 2018 Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Feb 2019 | Trial primary completion date: Apr 2017 --> Feb 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Phase classification, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC (clinicaltrials.gov) -  Apr 13, 2018   
    P2,  N=58, Recruiting, 
    Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Feb 2019 | Trial primary completion date: Apr 2017 --> Feb 2019 Phase classification: P1/2 --> P2 | Trial completion date: Dec 2020 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2019
  • ||||||||||  AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
    Enrollment change:  Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) -  Apr 11, 2018   
    P1/2,  N=40, Recruiting, 
    Phase classification: P1/2 --> P2 | Trial completion date: Dec 2020 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2019 N=190 --> 40